| |
CAR-T therapies have transformed treatment for certain hematological malignancies, but their use is limited. Ongoing research seeks to improve safety, efficacy, and lower costs, expanding their application. To learn more, download our white paper. 
|
|
Today’s Big NewsSep 18, 2024 |
|
With the acquisition of ZenBio, XenoTech, Cypex & others plus over 25 years of experience, BioIVT has unparalleled expertise providing both products and services for in vitro ADME research. View Capabilities. 
|
|
| By Nick Paul Taylor Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting cells outside the liver. |
|
|
|
By Nick Paul Taylor Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer. A phase 1 trial that combined the drug candidate with bevacizumab reported a 21.9% response rate, including signs of efficacy in patients with liver metastases and prior immunotherapy use. |
By James Waldron After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided that a planned advisory committee meeting won’t be required. |
Sponsored by Avacare Clinical Research Network With intricate protocols and shifting regulatory demands, it’s more difficult than ever to find and keep participants, as well as gather reliable data. |
|
Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies. 
|
|
By James Waldron Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy therapy, Japan’s Nippon Shinyaku has signed off on $35 million in cash and a stock purchase to secure the same deal in Europe. |
By Darren Incorvaia A drug candidate based on aprepitant was reported to reduce the brain area of astrocytes and improve cognitive function in a mouse model. Hoth Therapeutics reported the preclinical findings. |
By Darren Incorvaia For Ichnos Glenmark Innovation, good things come in threes. The alliance between Ichnos Sciences and Glenmark Pharmaceuticals has developed a trispecific, T-cell activating antibody that shrank multiple myeloma tumors in mice and killed cancer cells in human tissue more effectively than Janssen’s Tecvayli. |
By Fraiser Kansteiner Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. The crown jewel of the deal is undoubtedly Vtama, Dermavant’s steroid-free cream for plaque psoriasis, which is looking at a major expansion opportunity in eczema. |
By Heather Landi Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more accessible to consumers. |
By Conor Hale The FDA is getting the word out regarding a recall effort from Zimmer Biomet, related to its discontinued CPT hip implant and its potential link to fractures of the thigh bone after placement. |
By Angus Liu An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. |
|
|---|
|
|
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
